Abstract: 【Abstract】Anemia is a common complication and is related to progression of the kidney disease, longterm survival and adverse cardiovascular events in chronic kidney disease patients. Many new drugs can be clinically used to treat the anemia, including hypoxia-inducible factor prolyl hydroxylase inhibitors, new intravenous iron reagents, long-acting erythropoietin, etc. This article summarizes the progresses in the treatment of renal anemia so as to provide the evidence-based methods for clinical management of renal anemia.

Key words: Chronic kidney disease, Anemia, Erythropoiesis-stimulating agent, Hypoxia-inducible factor prolyl hydroxylase inhibitor